Clinical - ABL SA : ABL SA

Read more

EMRs - Registries - Integration tool

Read more

Clinical solutions

Discover our solutions

Clinical applications

Discover our applications

Advanced Biological Laboratories (ABL) S.A Inks Licensing Agreement with the Institut Pasteur for HPV RNA-Seq Technology

Apr 22, 2025

HPV Transcriptome as a Game-Changing Biomarker for Detection, Genotyping, and Monitoring of HPV-Associated Cervical High-Grade Cytology LUXEMBOURG, LUXEMBOURG, April 22, 2025 /EINPresswire.com/ — Advanced Biological Laboratories (ABL), a diagnostics company, headquartered in Luxembourg, is ple…
Read more
ABL Inks Know-How License and Transfer Agreement for the Fast Track Diagnostics PCR Portfolio from Siemens Healthineers

Feb 06, 2025

ABL and affiliates plan to start the production and commercialization of new UltraGene products based on PCR tests previously supplied by Fast Track Diagnostics ABL Diagnostics SA (EPA:ABLD) LUXEMBOURG VILLE, LUXEMBOURG, February 3, 2025 /EINPresswire.com/ — Advanced Biological Laboratories (A…
Read more
Webinar: E-AHPBA–ESSO–ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy

Nov 14, 2023

22.11.2023 at 4:30 to 6:00 p.m. (CET) These European guidelines for the preoperative measurement of liver function were published in June of this year. This represents an important milestone for the use of the LiMAx test and underlines its importance for the safety of patients and surgeons. In our w…
Read more

CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease

Jul 11, 2023

PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, and Humedics GmbH, a le…
Read more
ABL SA group acquires Berlin based Medtech company Humedics

Dec 15, 2022

ABL SA acquires the company Humedics Gmbh to extend the use of a robust, well-known, and CE-marked technology intended to be used for liver function measurement. Financial terms are not disclosed. Doctor Chalom Sayada, founder of the ABL SA and managing director of the Humedics declared: “We are pr…
Read more
Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA

Sep 02, 2022

On September 1st 2022, Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merged into ABL Diagnostics SA (ABLD), a worldwide leading international company, listed on Euronext Paris compartment C (ISIN FR001400AHX6), offering innovative and proprietary molecular biology assays an…
Read more

REALISATION DE LA FUSION

Aug 31, 2022

Paris, le 31 août 2022, Lors de la réunion du 3 août 2022 et dans le prolongement des communications effectuées à ce sujet, l’assemblée générale des actionnaires de la société ABL Diagnostics (la « Société ») a approuvé le projet de fusion-absorption de la société Advanced Biological Laboratories Fe…
Read more
WHO algorithm v2021-06 for Tuberculosis resistance now available!

Jul 26, 2022

We are pleased to announce the immediate availability of the WHO Catalog of Mutations (version 2021-06) in BacterioChek-TB, intended to be used for Mycobacterium tuberculosis drug resistance assessement.
ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™”

Jun 28, 2022

The UltraGene™ Assay SARS-CoV-2 PrimeChek™ is a CE-IVD marked real-time RT-PCR test intended for the qualitative detection of RNA from the SARS-CoV-2 in upper respiratory specimens from individuals suspected of COVID-19 by their healthcare provider.